Frommelt, Fabian https://orcid.org/0000-0003-3666-8005
Ladurner, Rene https://orcid.org/0000-0001-9261-7304
Goldmann, Ulrich https://orcid.org/0000-0003-1120-6912
Wolf, Gernot https://orcid.org/0000-0002-3943-8662
Ingles-Prieto, Alvaro https://orcid.org/0000-0002-5409-8571
Lineiro-Retes, Eva https://orcid.org/0000-0002-3812-8400
Gelová, Zuzana https://orcid.org/0000-0003-4783-1752
Hopp, Ann-Katrin https://orcid.org/0000-0002-2594-4070
Christodoulaki, Eirini https://orcid.org/0000-0001-9834-1257
Teoh, Shao Thing https://orcid.org/0000-0002-5938-258X
Leippe, Philipp https://orcid.org/0000-0002-1109-5610
Santini, Brianda L https://orcid.org/0000-0001-7539-8680
Rebsamen, Manuele https://orcid.org/0000-0001-6172-4211
Lindinger, Sabrina https://orcid.org/0009-0009-6822-9980
Serrano, Iciar https://orcid.org/0009-0005-9476-534X
Onstein, Svenja https://orcid.org/0000-0003-3309-1474
Klimek, Christoph https://orcid.org/0009-0004-7036-8799
Barbosa, Barbara https://orcid.org/0000-0001-9931-4402
Pantielieieva, Anastasiia https://orcid.org/0009-0005-9517-2570
Dvorak, Vojtech https://orcid.org/0000-0002-9496-370X
Hannich, Thomas J https://orcid.org/0000-0002-2286-4956
Schoenbett, Julian
Sansig, Gilles https://orcid.org/0009-0003-5427-1316
Mocking, Tamara A M https://orcid.org/0000-0001-6490-4429
Ooms, Jasper F https://orcid.org/0009-0009-8667-0980
IJzerman, Adriaan P https://orcid.org/0000-0002-1182-2259
Heitman, Laura H https://orcid.org/0000-0002-1381-8464
Sykacek, Peter https://orcid.org/0000-0001-8800-8354
Reinhardt, Juergen https://orcid.org/0000-0002-8226-5429
Müller, André C https://orcid.org/0000-0002-0608-8176
Wiedmer, Tabea https://orcid.org/0000-0002-0355-9315
Superti-Furga, Giulio https://orcid.org/0000-0002-0570-1768
Funding for this research was provided by:
Innovative Medicines Initiative 2 (777372)
Austrian Academy of Sciences
Article History
Received: 17 October 2024
Revised: 28 March 2025
Accepted: 11 April 2025
First Online: 12 May 2025
Disclosure and competing interests statement
: GS-F is a co-founder and owns shares of Solgate GmbH, an SLC-focused company.